Qureight provides an AI-powered platform for analyzing complex healthcare data, including medical imaging, clinical trial results, and biomarkers, to support drug development in lung and heart diseases. By enabling real-time data curation, central image reads, and machine learning-driven insights, it helps biopharma companies and research organizations streamline clinical trials, reduce development timelines, and improve patient selection.
Funding
$30.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ALCAGVHH+3Founders
Product
Problem
Drug development for lung and heart diseases is a lengthy process that requires analysis of complex healthcare data, including medical imaging, clinical trial results, and biomarkers. Traditional methods of data curation and analysis can be slow and inefficient, leading to prolonged clinical trials and delayed drug approvals. Identifying relevant endpoints and improving patient selection for clinical trials also presents a significant challenge.
Solution
Qureight offers an AI-powered platform that accelerates drug development by enabling real-time data curation and AI-driven decision-making. The platform facilitates collaborative analysis of imaging, clinical data, and biomarkers, providing a connected view of disease. By applying machine learning algorithms to complex healthcare data, including clinical trial images and physiological data, Qureight helps biopharma companies and research organizations streamline clinical trials, reduce development timelines, and improve patient selection. The platform's AI-guided workflows and central image reads, combined with cloud-based technology, enable faster and more efficient analysis.
Target Audience
Qureight's primary customers are biopharma companies, contract research organizations (CROs), and hospitals involved in drug development for lung and heart diseases.
Features
- AI-powered data analysis on complex healthcare data, including clinical trial images, physiological data, and blood-based biomarkers
- Machine learning-based image algorithms for CT scans
- AI-assisted workflows and central image reads with cloud-based technology
- Zero-footprint medical imaging viewing with annotation capabilities and ML model execution in the cloud
- Generation of synthetic study arms
- AI-powered quantitative imaging analysis of CT scans, including quantification of lung volumes, airways, pulmonary vessels, and fibrosis
- ISO13485 certified technology software for AI-related data analysis
- Data security compliant with GDPR, HIPAA, and 21 CFR Part 11